(ALGS) Aligos Therapeutics - Ratings and Ratios
Hepatitis B, NASH, Coronavirus, Therapeutics, Clinical
ALGS EPS (Earnings per Share)
ALGS Revenue
Description: ALGS Aligos Therapeutics October 19, 2025
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharma focused on novel small-molecule, capsid-modulator, and siRNA therapeutics targeting viral infections and liver diseases, notably non-alcoholic steatohepatitis (NASH) and chronic hepatitis B (CHB).
Its lead NASH candidate, ALG-055009, is a thyroid-hormone-receptor-β (THR-β) agonist currently in a Phase 2a trial. The company also reports a capsid-assembly modulator (ALG-000184) that completed a Phase 1b study for CHB, and an siRNA candidate (ALG-125755) in Phase I for the same indication. A separate antiviral program, ALG-097558, is in Phase 2 testing for coronavirus protease inhibition.
Aligos has built a network of strategic partnerships: a discovery and development collaboration with Merck on NASH-directed oligonucleotides; licensing deals with Emory University and Luxna Biotech for HBV capsid-modulator technology; and a joint research agreement with KU Leuven on coronavirus protease inhibitors, plus a clinical collaboration with Xiamen Amoytop Biotech.
From a market-size perspective, the global NASH therapeutic market is projected to exceed $30 billion by 2030, driven by rising obesity rates and limited approved treatments. Meanwhile, the CHB market remains sizable, especially in Asia, where prevalence exceeds 5 % of the adult population, creating a steady demand pipeline for curative agents.
As of the latest public filing (Q2 2025), Aligos reported approximately $70 million in cash and equivalents, giving it an estimated 12-month runway assuming current burn rates, but this figure is sensitive to trial enrollment speed and any upcoming financing events.
Sector-wide, biotech firms with early-stage liver-disease pipelines have historically commanded premium valuations when they demonstrate biomarker-driven efficacy signals, yet they also face heightened regulatory risk and capital-intensity, underscoring the importance of tracking cash burn and milestone payments.
For a deeper quantitative assessment, you may explore the ValueRay platform, which aggregates peer-adjusted metrics and scenario analyses for biotech pipelines.
ALGS Stock Overview
| Market Cap in USD | 57m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-10-16 |
ALGS Stock Ratings
| Growth Rating | -72.2% |
| Fundamental | 44.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -33.9% |
| Analyst Rating | 4.67 of 5 |
ALGS Dividends
Currently no dividends paidALGS Growth Ratios
| Growth Correlation 3m | -19.6% |
| Growth Correlation 12m | -51.1% |
| Growth Correlation 5y | -91.5% |
| CAGR 5y | -33.00% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.36 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.54 |
| Sharpe Ratio 12m | 0.17 |
| Alpha | -70.55 |
| Beta | 2.774 |
| Volatility | 86.40% |
| Current Volume | 152.6k |
| Average Volume 20d | 97.8k |
| Stop Loss | 6.6 (-7%) |
| Signal | -0.64 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-74.2m TTM) > 0 and > 6% of Revenue (6% = 190.4k TTM) |
| FCFTA -0.56 (>2.0%) and ΔFCFTA 22.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3393 % (prev 954.0%; Δ 2439 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.56 (>3.0%) and CFO -74.9m <= Net Income -74.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.4m) change vs 12m ago 234.7% (target <= -2.0% for YES) |
| Gross Margin 70.70% (prev 65.61%; Δ 5.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.61% (prev 7.32%; Δ -4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -42.55 (EBITDA TTM -73.5m / Interest Expense TTM -1.78m) >= 6 (WARN >= 3) |
Altman Z'' -32.10
| (A) 0.80 = (Total Current Assets 127.9m - Total Current Liabilities 20.3m) / Total Assets 134.7m |
| (B) -4.39 = Retained Earnings (Balance) -590.8m / Total Assets 134.7m |
| warn (B) unusual magnitude: -4.39 — check mapping/units |
| (C) -0.62 = EBIT TTM -75.6m / Avg Total Assets 121.8m |
| (D) -17.98 = Book Value of Equity -590.4m / Total Liabilities 32.8m |
| Total Rating: -32.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.22
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield 127.7% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda 0.16 = 2.48 |
| 7. RoE -123.9% = -2.50 |
| 8. Rev. Trend -85.24% = -6.39 |
| 9. EPS Trend -57.31% = -2.87 |
What is the price of ALGS shares?
Over the past week, the price has changed by -13.41%, over one month by -30.53%, over three months by -11.69% and over the past year by -24.06%.
Is Aligos Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALGS is around 4.44 USD . This means that ALGS is currently overvalued and has a potential downside of -37.46%.
Is ALGS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.3 | 1030.3% |
| Analysts Target Price | 80.3 | 1030.3% |
| ValueRay Target Price | 5.2 | -26.5% |
ALGS Fundamental Data Overview November 04, 2025
P/S = 18.0683
P/B = 0.6988
Beta = 2.774
Revenue TTM = 3.17m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -73.5m USD
Long Term Debt = 6.88m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.54m USD (from shortTermDebt, last quarter)
Debt = 6.88m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.9m USD (from netDebt column, last quarter)
Enterprise Value = -58.8m USD (57.3m + Debt 6.88m - CCE 123.1m)
Interest Coverage Ratio = -42.55 (Ebit TTM -75.6m / Interest Expense TTM -1.78m)
FCF Yield = 127.7% (FCF TTM -75.1m / Enterprise Value -58.8m)
FCF Margin = -2367 % (FCF TTM -75.1m / Revenue TTM 3.17m)
Net Margin = -2337 % (Net Income TTM -74.2m / Revenue TTM 3.17m)
Gross Margin = 70.70% ((Revenue TTM 3.17m - Cost of Revenue TTM 930.0k) / Revenue TTM)
Gross Margin QoQ = 73.16% (prev 100.0%)
Tobins Q-Ratio = -0.44 (set to none) (Enterprise Value -58.8m / Total Assets 134.7m)
Interest Expense / Debt = 186.0% (Interest Expense 12.8m / Debt 6.88m)
Taxrate = -1.18% (negative due to tax credits) (185.0k / -15.7m)
NOPAT = -76.5m (EBIT -75.6m * (1 - -1.18%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 6.31 (Total Current Assets 127.9m / Total Current Liabilities 20.3m)
Debt / Equity = 0.07 (Debt 6.88m / totalStockholderEquity, last quarter 101.9m)
Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -11.9m / EBITDA -73.5m)
Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -11.9m / FCF TTM -75.1m)
Total Stockholder Equity = 59.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.07% (Net Income -74.2m / Total Assets 134.7m)
RoE = -123.9% (Net Income TTM -74.2m / Total Stockholder Equity 59.9m)
RoCE = -113.3% (out of range, set to none) (EBIT -75.6m / Capital Employed (Equity 59.9m + L.T.Debt 6.88m))
RoIC = -127.8% (out of range, set to none) (NOPAT -76.5m / Invested Capital 59.9m)
WACC = 14.50% (E(57.3m)/V(64.2m) * Re(16.24%) + (debt cost/tax rate unavailable))
Discount Rate = 16.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -9.62%
Fair Price DCF = unknown (Cash Flow -75.1m)
EPS Correlation: -57.31 | EPS CAGR: -3.21% | SUE: -0.38 | # QB: 0
Revenue Correlation: -85.24 | Revenue CAGR: -40.94% | SUE: 0.23 | # QB: 0
Additional Sources for ALGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle